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ORIGINAL ARTICLE
Sotagliflozin Added to Optimized Insulin Therapy Leads
to Lower Rates of Clinically Relevant Hypoglycemic Events
at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Thomas Danne, MD,1 Jeremy Pettus, MD,2 Andrea Giaccari, MD, PhD,3 Bertrand Cariou, MD, PhD,4
Helena Rodbard, MD, FACP, MACE,5 Stuart A. Weinzimer, MD,6 Mireille Bonnemaire, MD, MBA, MS,7
Sangeeta Sawhney, MD,8 John Stewart, MSc,9 Stella Wang, MS, MPH,9 Rita de Cassia Castro, MD,9
and Satish K. Garg, MD10
Abstract
Background: Hypoglycemia rates usually increase when insulin treatment is intensified to improve glycemic
control. We evaluated (post hoc) hypoglycemic rates in adult patients with type 1 diabetes (T1D) on sotagli-
flozin (a dual sodium-glucose cotransporter [SGLT] 1 and 2 inhibitor) in two phase 3, 52-week clinical trials
(inTandem 1 and 2; NCT02384941 and NCT02421510).
Materials and Methods: We analyzed rates of documented hypoglycemia (level 1, blood glucose ‡54 to
<70 mg/dL) and clinically important hypoglycemia (level 2, glucose <54 mg/dL) in a patient-level pooled
analysis (n = 1362) using a negative binomial model adjusted for hemoglobin A1c (HbA1c) at 52 weeks in
patients receiving placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg.
Results: Rates of level 1 hypoglycemia events per patient-year were 58.25 (95% confidence interval: 50.26–
67.50) with placebo, 44.86 (38.83–51.82; P= 0.0138 vs. placebo) with sotagliflozin 200 mg, and 45.68 (39.52–
52.81; P= 0.0220) with sotagliflozin 400 mg. Sotagliflozin was also associated with lower rates of level 2
hypoglycemia: 15.95 (14.37–17.70), 11.51 (10.39–12.76; P< 0.0001), and 11.13 (10.03–12.35; P < 0.0001) for
placebo and sotagliflozin 200 and 400 mg, respectively. The difference in rates of hypoglycemia with so-
tagliflozin versus placebo became more pronounced as HbA1c decreased.
Conclusions: At week 52, level 1 and 2 hypoglycemia events were 22% to 30% less frequent with sotagliflozin
added to optimized insulin therapy versus placebo in adults with T1D at any HbA1c level, with greater
differences at lower HbA1c values. These findings support the use of sotagliflozin as an insulin adjunct in T1D.
Keywords: Sotagliflozin, Hypoglycemia, HbA1c, Efficacy beyond HbA1c, inTandem, SGLT1/SGLT2
inhibitors.
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Introduction
As hemoglobin A1c (HbA1c) levels decrease, hypo-glycemia risk increases for patients with diabetes who
depend on insulin therapy.1,2 Nonsevere hypoglycemia—
often a daily occurrence for many patients—impairs well-
being and reduces productivity, and severe hypoglycemia
may result in seizures, coma, or death.3–7 In the international
Hypoglycemia Assessment Tool (HAT) study, which in-
volved *8000 adults with type 1 diabetes (T1D), the esti-
mated annual rate of any hypoglycemia was 73.3 episodes per
patient-year. The rate of severe hypoglycemia was 4.9 events
per patient-year, and up to 5% of HAT study participants
reported being admitted to the hospital for hypoglycemia
during the 4-week study period.7 Hypoglycemia places a
substantial cost burden on the individual and society and
poses a major barrier to achieving and maintaining optimal
blood glucose levels.6–8 However, the increased risk of dia-
betes complications resulting from chronic hyperglycemia
could also be considered a cost for patients who avoid in-
tensifying insulin therapy for fear of hypoglycemia. There-
fore, therapies are needed that improve overall glycemic
control while reducing the risk of hypoglycemia.
Pramlintide, the only agent currently approved as an
insulin-adjunct for the treatment of T1D in the United States,
reduces HbA1c but is associated with an increased risk of
severe hypoglycemia and gastrointestinal side effects.9,10
Recently, interest has focused on the potential of sodium-
glucose cotransporter (SGLT) inhibitors in combination with
insulin, as these agents have been shown to improve glucose
control without increasing the risk of hypoglycemia or weight
gain in patients with T1D.11–18 Sotagliflozin is a novel dual
inhibitor of SGLT1 and SGLT2 that delays glucose absorption
in the proximal gastrointestinal tract through SGLT1 inhibition,
causing a blunting and reduction of postprandial glucose, and
that decreases renal glucose reabsorption through SGLT2 in-
hibition.19–21 In the inTandem phase 3 program, consisting of
one 24-week and two 52-week international, randomized,
double-blind, placebo-controlled trials of sotagliflozin in com-
bination with insulin in T1D, sotagliflozin significantly reduced
HbA1c, fasting plasma glucose, body weight, and blood
pressure (in patients with systolic blood pressure [SBP]
‡130 mmHg), and increased the proportion of patients achiev-
ing HbA1c <7.0%. Furthermore, decreases in documented hy-
poglycemia were observed in each inTandem trial.11–14
In the inTandem phase 3 trials, the rates of documented
hypoglycemia were evaluated as plasma glucose £70 and
£55 mg/dL.11–13 To further examine the incidence of hypo-
glycemia when sotagliflozin is used in combination with
optimized insulin treatment, we conducted an exploratory
post hoc analysis of pooled data from inTandem1 and 2 to
compare the rate of hypoglycemia at each week 52 HbA1c
value among patients receiving placebo and sotagliflozin over
1 year. For this post hoc analysis, we analyzed hypoglycemia
incidence according to cutpoints recommended by the Ameri-
can Diabetes Association (ADA) and European Association for
the Study of Diabetes (EASD), defined as level 1 (<70 mg/dL
but ‡54 mg/dL) and level 2 hypoglycemia (<54 mg/dL).22,23
Research Design and Methods
An exploratory post hoc analysis was conducted using
pooled hypoglycemia and HbA1c data from week 52 of two
phase 3, 52-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group trials of oral sotagliflozin
200 or 400 mg once daily in combination with optimized
insulin in adults with T1D who had inadequate glycemic
control on insulin alone. The trials were conducted in the U.S.
and Canada (inTandem1 [NCT02384941]) and Europe and
Israel (inTandem2 [NCT02421510]). The Institutional Re-
view Boards for each study center or the local Ethics Com-
mittees approved the protocol, consent form, and associated
documents. All patients provided written informed consent.
Trial designs have been previously described.12,13
Study population
The inTandem program included men and nonpregnant
women aged ‡18 years who had T1D treated with insulin
delivered via multiple daily injections or continuous subcu-
taneous insulin infusion whose HbA1c was between 7.0%
and 11.0% at screening. Full details have been previously re-
ported.12,13 This pooled post hoc analysis included trial partic-
ipants for whom an HbA1c value at week 52 was available.
Interventions
Beginning 6 weeks before randomization, insulin therapy
was optimized by adjusting basal and bolus doses to maintain
fasting or preprandial blood glucose between 80 and 130 mg/dL
and 1- to 2-h postprandial glucose £180 mg/dL based on self-
monitored blood glucose. Patients were randomly assigned in a
1:1:1 ratio to placebo, sotagliflozin 200 mg, or sotagliflozin
400 mg, given as two tablets administered orally once daily.
After randomization, participants entered a 24-week, double-
blind core treatment period followed by a 28-week double-blind
extension period. Insulin optimization continued throughout
the 52-week trial for all patients, with guidance from an in-
dependent insulin dose monitoring committee from the start
of the insulin optimization period through week 24 and
investigator-led optimization thereafter.12,13
Endpoints
The endpoints of this post hoc analysis included the
number of level 1 hypoglycemia events per patient-year of
exposure from baseline to endpoint (week 52), the number of
level 2 hypoglycemia events per patient-year of exposure
from baseline to week 52, and the incidence of positively
adjudicated severe (level 3) hypoglycemia from baseline to
week 52. Symptomatic and asymptomatic events were
counted and included together in the analysis. In the original
study protocols, level 1 hypoglycemia was defined as plasma
glucose £70 mg/dL and level 2 as plasma glucose £55 mg/dL.
To be consistent with ADA and EASD criteria,22,23 level 1
and 2 hypoglycemia were defined more strictly for this post
hoc analysis: level 1, plasma glucose <70 mg/dL but
‡54 mg/dL; level 2, plasma glucose <54 mg/dL; and level 3
(severe), hypoglycemia was defined as any event that re-
quired assistance from another person or during which the
patient lost consciousness or had a seizure (same definition
used in the original inTandem studies).12,13
Statistical methods
The estimated number of treatment emergent, documented
hypoglycemia events per patient-year of exposure from
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baseline to endpoint was adjusted based on HbA1c at week
52, and 95% confidence intervals (CI) were determined. All
symptomatic and asymptomatic hypoglycemic events were
counted that occurred between day 1 and the end of treatment
for which a documented blood glucose value was ‡54 and
<70 mg/dL (level 1) or <54 mg/dL (level 2). The annualized
rates were estimated by dividing the total number of events
by the total exposure in years using a negative binomial
model, with the total number of events per patient occurring
from baseline to endpoint as the response variable, treatment
and week 52 HbA1c as covariates, and log-transformed pe-
riod duration (period defined as from baseline to endpoint) as
an offset variable. As this is a post hoc analysis, P values were
used for exploratory purposes only.
Results
The pooled analysis from inTandem 1 and 2 trials included
448 patients receiving placebo, 460 receiving sotagliflozin
200 mg, and 454 receiving sotagliflozin 400 mg. Table 1 lists
baseline demographics.
At week 52, the mean HbA1c was 7.7%– 0.9% (range
5.7%–11.9%), 7.4% – 0.9% (5.6%–12.3%), and 7.3%– 0.9%
(5.5%–11.5%) in the placebo and sotagliflozin 200 and
400 mg groups, respectively.
The adjusted number of events per patient-year of level 1
hypoglycemia was 58.25 (95% CI: 50.26–67.50) with pla-
cebo, 44.86 (38.83–51.82; P = 0.0138) with sotagliflozin
200 mg, and 45.68 (39.52–52.81; P = 0.0220) with sotagli-
flozin 400 mg. The rates of level 2 hypoglycemia were 15.95
(14.37–17.70) in the placebo group, 11.51 (10.39–12.76;
P < 0.0001) in the sotagliflozin 200 mg group, and 11.13
(10.03–12.35; P< 0.0001) in the 400 mg dose group. The
number of hypoglycemic events plotted versus HbA1c at
week 52 (Fig. 1) was significantly reduced with sotagliflozin
200 and 400 compared with placebo (level 1, P< 0.05; level
2, P < 0.001).
Level 1 nocturnal hypoglycemia occurred at rates of 8.04
(95% CI: 6.97–9.27) events per patient-year in the placebo
group, 6.30 (5.47–7.24; P= 0.0177 vs. placebo) with so-
tagliflozin 200 mg, and 6.25 (5.42–7.19; P = 0.0148) with
sotagliflozin 400 mg. Rates of level 2 nocturnal hypoglyce-
mia were 2.29 (2.00–2.64), 1.80 (1.56–2.06; P = 0.0149), and
1.70 (1.47–1.95; P= 0.0032) events per patient-year with
placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, re-
spectively.
Positively adjudicated severe (level 3) hypoglycemia oc-
curred in 28 (6.3%) patients who received placebo and 12
(2.6%; P = 0.0091 vs. placebo) and 10 (2.2%; P = 0.0026 vs.
placebo) patients receiving sotagliflozin 200 and 400 mg,
respectively.
Discussion
In this exploratory post hoc analysis of hypoglycemia as a
function of HbA1c in patients with T1D receiving sotagli-
flozin or placebo in combination with optimized insulin
therapy, level 1 hypoglycemia event rates were 22% lower
with both doses of sotagliflozin compared to placebo, and
level 2 was 28% and 30% lower with sotagliflozin 200 and
400 mg, respectively. After a year of treatment, mean HbA1c
was 7.7%, 7.4%, and 7.3% with placebo and sotagliflozin 200
and 400 mg, respectively, and ranged from 5.5% to 12.3%
across treatment groups. For any given HbA1c value, so-
tagliflozin 200 and 400 mg were associated with a substan-
tially lower incidence of hypoglycemia than placebo. The
proportions of patients reporting severe hypoglycemia were
lower among those receiving sotagliflozin (2.6% and 2.2%
with 200 and 400 mg, respectively) than placebo (6.3%).
Over 95% of study participants experienced at least one
level 1 or level 2 event during the studies. With an incidence
this high, data on rates (events per patient year), rather than
incidence (proportions of patients affected), provide a more
sensitive measure of risk. However, because the incidence of
level 3 severe hypoglycemia (proportion of patients with at
least 1 event) was much lower than that of level 1 and 2
hypoglycemia, and patients tended not to experience multiple
episodes of the event, level 3 hypoglycemia is reported as
Table 1. Baseline Demographics of the Exploratory Analysis Population (Patients with a Hemoglobin
A1c Value at Week 52)
Placebo
(n = 448)
Sotagliflozin 200mg
(n = 460)
Sotagliflozin 400mg
(n = 454)
Mean age – SD, years 42.6 – 13.3 44.8 – 13.6 44.5 – 13.0
Female sex, n (%) 207 (46.2) 224 (48.7) 227 (50.0)
Race, n (%)
White 420 (93.8) 434 (94.3) 432 (95.2)
Black 8 (1.8) 9 (2.0) 6 (1.3)
Asian 4 (0.9) 7 (1.5) 4 (0.9)
Native Hawaiian or other Pacific
Islander
2 (0.4) 2 (0.4) 0
American Indian or Alaska Native 0 1 (0.2) 0
Other 14 (3.1) 7 (1.5) 12 (2.6)
Mean diabetes duration– SD, years 21.29 – 12.04 21.95 – 12.34 21.31 – 12.16
Mean BMI – SD, kg/m2 28.59– 5.28 28.88– 5.40 28.99 – 5.11
Insulin therapy, n (%)
CSII 190 (42.4) 195 (42.4) 190 (41.9)
MDI 258 (57.6) 265 (57.6) 264 (58.1)
Mean total daily insulin – SD (IU/kg) 65.0 – 36.4 62.8 – 35.2 64.1 – 34.3
BMI, body mass index; CSII, continuous subcutaneous insulin infusion; MDI, multiple daily insulin injections; SD, standard deviation.
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incidence, as it is a more meaningful way to assess the impact
of these events on patients.
The inverse relationship between HbA1c and hypoglyce-
mia is a perennial challenge to optimal management of T1D.
Patients who intensify insulin regimens to optimize glycemia
and lower their risk of diabetic complications may experience
more frequent hypoglycemic events. Hypoglycemia, and fear
of it, negatively affects quality of life and ultimately under-
mines attempts to improve glycemic control.7,24–26 In the 52-
week inTandem1 and 2 trials, sotagliflozin adjunct to insulin
significantly decreased the incidence of clinically significant
documented hypoglycemia (defined as plasma glucose
£55 mg/dL in the main trials) relative to placebo, and posi-
tively adjudicated severe hypoglycemia occurred in 7.4%,
5.7%, and 4.4% of patients who received placebo, sotagli-
flozin 200 mg, and sotagliflozin 400 mg, respectively, in the
pivotal trials. The use of sotagliflozin in combination with
insulin also significantly reduced mean HbA1c, weight, in-
sulin doses, and SBP (in patients with SBP ‡130 mmHg at
baseline).12,13 As shown in a continuous glucose monitoring
FIG. 1. Estimated number of hypoglycemia events per patient-year as a function of HbA1c at week 52. (A) Level 1
hypoglycemia, defined as plasma glucose <70 mg/dL but ‡54 mg/dL. (B) Level 2 hypoglycemia, plasma glucose
<54 mg/dL. Gray circles (placebo), green diamonds (sotagliflozin 200 mg), and blue squares (sotagliflozin 400 mg) indicate
the rate of hypoglycemia at each HbA1c value, and the corresponding shaded areas depict the 95% CI. The box in each
panel highlights the difference in HbA1c at equivalent rates of hypoglycemia. HbA1c, hemoglobin A1c; CI, confidence
interval.
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(CGM) substudy, sotagliflozin also reduced multiple mea-
sures of glycemic variability and significantly increased time
in range, demonstrating reduced time in hyperglycemia
without an increase in time <70 mg/dL.27 These changes were
accompanied by significant improvements in treatment sat-
isfaction and diabetes distress scales in the overall study
populations.12,13
The present analysis supports these findings by demon-
strating that sotagliflozin reduces the rate of ADA/EASD-
defined level 1 (<70 mg/dL but ‡54) and level 2 (<54 mg/dL)
hypoglycemia.22,23 The rates of level 1 and 2 hypoglycemia
were similar with sotagliflozin 200 and 400 mg, but the
proportion of patients reporting severe hypoglycemia was
lowest in the 400 mg group.
Along with the improvements in glycemic variability ob-
served in the inTandem CGM substudy, the reduction in
hypoglycemia across the spectrum of HbA1c evident from
the present analysis may at least partly account for the im-
provements in patient-reported outcomes seen in the main
trials.12,13,27 In this study, patients receiving sotagliflozin
who achieved an HbA1c of 7.0% experienced the same in-
cidence of level 1 hypoglycemia (plasma glucose <70 mg/dL
but ‡54 mg/dL) as patients who had an HbA1c of 8.0% while
receiving insulin alone, and the same rate of clinically sig-
nificant, level 2 hypoglycemia (plasma glucose <54 mg/dL)
occurred with an HbA1c of 6.5% in the sotagliflozin group
and 8.0% in the placebo group. Thus, patients whose HbA1c
is lowered with the combination of sotagliflozin and insulin
are less likely to experience hypoglycemia than those whose
HbA1c reductions of a similar magnitude are achieved with
insulin intensification alone.
In phase 3 studies with dapagliflozin in T1D (DEPICT
trials), a final HbA1c of*8.0% was achieved after 24 weeks
of treatment with dapagliflozin 10 mg, and the rates of
documented and severe hypoglycemia were similar in the
dapagliflozin and placebo groups.16,17 In phase 3 trials, em-
pagliflozin 25 mg was associated with an HbA1c of*7.8%
after 26 (EASE-3) and 52 (EASE-2) weeks of treatment.
Investigator-reported documented hypoglycemia and severe
hypoglycemia were similar between treatment groups, al-
though patient diary reports of symptomatic hypoglycemia
were lower with empagliflozin than with placebo.18 After 52
weeks, sotagliflozin 400 mg was associated with an HbA1c of
7.2% (inTandem1) and 7.4% (inTandem2), with lower rates
of hypoglycemia compared to insulin alone.12,13 Overall, the
results of these trials suggest that the lower the achieved
HbA1c at the end of the trial, the higher the difference in rates
of hypoglycemia, which tend to be lower in groups treated
with the SGLT inhibitor.
Hypoglycemia has a greater impact on patients’ day-to-
day lives than hyperglycemic emergencies. Twice as many
T1D Exchange participants reported an episode of severe
hypoglycemia as diabetic ketoacidosis (DKA) over the pre-
vious 3 months.28 More emergency room visits are reported
for severe hypoglycemia than DKA.29 Nevertheless, the risk
of DKA is increased with SGLT inhibitors, including so-
tagliflozin.30 Sotagliflozin treatment was associated with an
increased risk of DKA in the inTandem trials.11–13 Similar
increases in DKA in phase 3 T1D trials were reported with
the dosages of dapagliflozin and empagliflozin marketed for
the treatment of type 2 diabetes.16–18,31 Sotagliflozin 200 and
400 mg and dapagliflozin 5 mg have been approved by the
European Medicines Agency (EMA) as adjuncts to insulin in
T1D.32,33 Both agents are still under review by the U.S. Food
and Drug Administration (FDA). Clinicians using these
medications in insulin-using patients should implement ap-
propriate DKA risk-mitigation strategies as outlined in recent
publications.30,34
A limitation of this study was that the relationship between
hypoglycemia and insulin dose changes cannot be deter-
mined from the results presented here. In the year-long in-
Tandem trials, total insulin doses at 52 weeks were 6% to
12% lower with sotagliflozin compared with placebo, with
dose-dependent differences primarily driven by greater re-
ductions in bolus insulin with sotagliflozin 400 mg.12,13
In conclusion, after 52 weeks, the addition of sotagliflozin
to optimized insulin therapy was associated with a decrease
in overall, nocturnal, and severe hypoglycemia across all
HbA1c levels. Hypoglycemia increased as HbA1c decreased
in all groups, but the sotagliflozin groups experienced a re-
duced rate of hypoglycemia relative to placebo at lower
HbA1c levels. This approach could permit more patients to
reach their target HbA1c without incurring an increased risk
of hypoglycemia. Our data support the use of sotagliflozin in
combination with insulin for the treatment of T1D.
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